These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3228902)

  • 1. [A comparison of therapeutic effectiveness between rifamdin-regimen and rifampicin-regimen in pulmonary tuberculosis].
    Lu Q
    Zhonghua Jie He He Hu Xi Za Zhi; 1988 Aug; 11(4):225-7, 255. PubMed ID: 3228902
    [No Abstract]   [Full Text] [Related]  

  • 2. [A study on the therapeutic effect of rifamdin on pulmonary tuberculosis].
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1982 Apr; 5(2):74-7. PubMed ID: 6813082
    [No Abstract]   [Full Text] [Related]  

  • 3. [Recent report of short-term chemotherapy with rifamdin in pulmonary tuberculosis in rural areas].
    Qu SH; Meng ZR
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1984 Aug; 7(4):208-9, 253. PubMed ID: 6549552
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trial of rifampicin in the treatment of pulmonary tuberculosis in Lagos.
    Makanjuola OO
    Niger Med J; 1973 Jul; 3(3):156-7. PubMed ID: 16366352
    [No Abstract]   [Full Text] [Related]  

  • 5. Worsening of steroid dependent asthma : A possible role of rifampicin.
    Gupta D; Yadav S; Behera D; Jindal SK
    Indian J Chest Dis Allied Sci; 1995; 37(1):35-8. PubMed ID: 16892737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin.
    Goldberg SV; Hanson D; Peloquin CA
    Clin Infect Dis; 2003 Aug; 37(4):607-8. PubMed ID: 12905149
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-resistance tuberculosis among the foreign-born in Canada.
    Can Commun Dis Rep; 2005 Feb; 31(4):46-52. PubMed ID: 15712449
    [No Abstract]   [Full Text] [Related]  

  • 10. [Simultaneous resistance to rifampicin and isoniazid in patients with pulmonary tuberculosis].
    Ouedraogo M; Ouedraogo SM; Diagbouga S; Coulibaly G; Achi V; Domoua K; N'Dathz M; Yapi A
    Rev Mal Respir; 2000 Apr; 17(2):477-80. PubMed ID: 10859766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey.
    Sanders M; Van Deun A; Ntakirutimana D; Masabo JP; Rukundo J; Rigouts L; Fissette K; Portaelst F
    Int J Tuberc Lung Dis; 2006 Feb; 10(2):178-83. PubMed ID: 16499257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term results of treatment for drug-resistant pulmonary tuberculosis in socially adapted patients].
    Khodashova ML; Iuditskiĭ MV; Semenova OV
    Probl Tuberk Bolezn Legk; 2004; (3):26-8. PubMed ID: 15338896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombocytopenia--a rare but serious side effect of rifampicin.
    Shah NM; Venkatachalam S; Mehta Y; Balakrishnan C; Dubey SG; Mangat GK; Joshi VR
    J Assoc Physicians India; 1996 May; 44(5):359-60. PubMed ID: 9282598
    [No Abstract]   [Full Text] [Related]  

  • 15. [Rapid prediction of rifampin susceptibility of Mycobacterium tuberculosis].
    Rinder H
    Pneumologie; 1998 Feb; 52(2):91-2. PubMed ID: 9557056
    [No Abstract]   [Full Text] [Related]  

  • 16. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
    Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection.
    Haley CA; Stephan S; Vossel LF; Sherfy EA; Laserson KF; Kainer MA
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):160-7. PubMed ID: 18230248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The therapeutic action of Rifampicin, a derivative of 3-(4-methyl-1-piperazinyl-iminomethyl)-rifamycin SV, in pulmonary tuberculosis].
    Lucchesi M; Pallotta G; Rossi P; Sbampato M
    Ann Ist Carlo Forlanini; 1967; 27(3):199-227. PubMed ID: 5602885
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug-resistant pulmonary tuberculosis at the penitentiaries].
    Kononets AS
    Probl Tuberk Bolezn Legk; 2008; (12):60-3. PubMed ID: 19227326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed death from pulmonary tuberculosis: unsuspected subtherapeutic drug levels.
    Morehead RS
    South Med J; 2000 May; 93(5):507-10. PubMed ID: 10832953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.